The History and Future Prospects to Antibodies

The History and Future Prospects of Antibodies

It's fair to say that over the past two centuries research and treatment regarding the knowledge and applications of antibodies has come a long way from its early discoveries and basic understandings.

Who first recognise the potential of antibodies?

The existence of a component responsible for recognising infections was first brought to light in 1890 by Dr Emil von Behring and his partner Shibasabura Kitasato when the pair produced their landmark publication demonstrating the transfer of serum from animals immunised against Diphtheria into animals suffering from it could help cure them. So, it's thanks to this publication that specialised research began in order to have an understanding the components within the immune system which could be responsible for identifying infectious pathogens.

Where it all started?

However, just because the depths of the biochemistry were yet to be understood, vaccinations had been in practice for centuries prior to this in the far east. Scientists and medical practitioners where unaware of the existence of antibodies at this time but the first immunisation process is recorded to have taken place in China around 900AD.

How it works?

The principle of vaccination and immunisation developed by the Chinese is similar to how modern vaccines work, but these early days vaccination posed more risks that what we have today. The method was to deliberately cause a mild infection with unmodified pathogens. This was known as Variolation, named after the Variola virus which was used as the infective agent and was practiced through the 14th to 17th century.

The great breakthrough

The most well-known breakthrough in immunization records and vaccinology would be Edward Jenner’s smallpox vaccine in 1796. His vaccine against smallpox was developed by inoculating a boy with the fluid from a cowpox pustule, which gave the boy immunity to the similar but much more aggressive smallpox.

Behring and Kitasato’s publication of serum transfer was the cascade of the development of many antibody theories; In 1900 Paul Ehrlich is the man responsible for the proposition of the side-chain theory in which he hypothesised that there are side chain receptors on cells that bind to a given pathogen.


The immunology community often refer to Ehrlich as the father of modern immunology given that he was the first to propose a model for antibodies where the molecule consisted of multiple sites for binding to target sites. Now I know this article is about antibodies but all that’s been talked about is vaccine development, well as mentioned, Behring and Kitasato are the two who pioneered the beginning of antibody discovery. Before these two the community only knew how but not the why.


The antibodies in the modern times

Going forward in time, ahead of both Jenner and Berhing & Kitasato’s breakthroughs, In 1948 Dr Astrid Fagraeus researched into B cells and described that plasma B cells played a specific involvement with antibody development. This was further expanded on by Frank Burnet and David Talmage in 1957 when the two developed the clonal selection theory.

The theory

The clonal selection theory of antibodies states that: a B lymphocyte makes single specific antibody molecules that are determined before it encounters the antigen.

The leap forward

The 1970s were the biggest leaps in modern history with the progression of antibody knowledge and research prospects. With the first atomic structure of an antibody fragment published in 1973 the production of antibodies soon followed in 1975 by Georges Köhler and César Milstein with the creation of monoclonal antibodies.

The first commercial monoclonal antibody

The first licensed monoclonal antibody was Orthoclone OKT3, approved in 1986 it is a mouse monoclonal IgG2a antibody which detects CD3 antigens. OKT3 was used for preventing kidney transplant rejection therefore targeting CD3 presenting cells, its target cells were CD3 expressing T-lymphocytes.

 


 

PRODUCTION WAS LIMITED AND DIFFICULT. Early monoclonal antibody production was initially limited by the availability of suitable myeloma cell lines as well as hybridomas having the risks of being low yielding or genetically unstable. In 2009 it was found that E. coli is an excellent system for expressing antibody fragments and was then utilised to culture single-chain variable regions and antigen-binding fragments of antibodies. However, it has been noticed with using E. coli that synthesis of larger full-sized antibodies may be beyond the capabilities of the small microorganism.


How monoclonals are made now?

Immunisation with immunogen

The original monoclonal antibodies were created via injecting an immunogen into an animal, typically goats, mice and rabbits, in which the animal host will have an immune response. This process is monitored regularly.

Cell Fusion

The animal B cells are then removed and fused with a cancer myeloma cell in order to create an immortal cell line. Therefore, creating a mono-culture of B-cells all producing the same specific antibody. Each hybridoma is then producing a monoclonal antibody and is designated a specific epitope region of the antigen.

Production and purification

The monoclonal antibodies are then finally excreted by the B-cells into the cell culture media, where they can be extracted for further antigen binging affinity testing and purification.


LEGACY FROM THE 70's. This technique which was established in the 70’s is still used to this day, but with modern advances the process is much faster.


Antibodies in the 21st century

With the vast developments of biochemical and biotechnological techniques, a new method of generating monoclonal antibodies that is utilised greatly in the 21st century is by using phage display.

Phage display technique 

Phage display technique is the isolation of B-lymphocytes from human blood samples and further isolating the mRNA, converting it into cDNA in order to amplify the VH and VL segments.

The principle

These isolated and identified segments are then cloned into a vector next to the PIII protein which will be transfected into E. coli in order to create a library of 1010 cells.

Reproducibility of the process

Once the library is made, the same library can then be used to generate new antibodies and doesn’t have to be remade. No immunisations are required, and the process is done in vitro.

Advantages

This is a much faster way of creating antibodies in contrast to the old traditional method of immunisation of animals, waiting for their B cells to naturally produce the antibodies. A process which can take several months depending on the antibodies.

 

The future of antibodies

Now, future prospects involve utilising antibodies for various biomedical fields such as medicine and therapeutics. Research that includes the use of antibodies has been increasing steadily since the 50’s.

Antibodies in Medicine

Within medicine and therapeutics antibodies are now being applied to techniques like:

  • Biochemical assays for diagnostics via protein detection;
  • ELISA diagnostic techniques which use multiple antibodies to detect specific antigens for infectious disease diagnosis;
  • Provide an analysis of patients antibody profile;
  • Monoclonal antibodies are used to treat several diseases such as multiple sclerosis, rheumatoid; arthritis and psoriasis.
Detecting immunuglobins

Antibodies are also developed to detect immunoglobins as some of them can be useful indicators in diagnosis of many ailments and even utilising the detection of human chorionic gonadotropin for pregnancy tests kits?

Understanding the immune system

Their resourcefulness has proven to be incredibly useful and the greater understanding of the immune system has come a long way since early established methods of Variolation from over a thousand years ago.

Cancer research

Many researchers are looking into the influences antibodies can have on current issues like fighting cancer. There are many studies currently which are investigating the efficiency of antibody binding for targeting cancerous cells, assisting the bodies immunity in fighting against these harmful cells.

Infectious diseases

As technology advances and antibodies can be manipulated further and further it is hoped that some of the deadliest pathogenic infections like HIV and Malaria can be eradicated much like the great achievement of globally eradicating smallpox’s from the human population.

With their growing involvement within modern medicine, research, therapeutics and diagnostics antibodies are a versatile resource which we can generate limitlessly with techniques like phage display and cloning.


THE PIONEERS THAT CHANGE IT ALL. Those of the immunology field owe a great deed to the early pioneers of immunological studies like Emil von Behring and Shibasabura Kitasato, Edward Jenner and Paul Ehrlich.


References:

-Behring and Kitasato, “The Establishment of Diphtheria Immunity and Tetanus Immunity in Animals”, Dtsch Med Wochenschr, Volume 49, 1890;
-NHS.com “The History of Vaccination”, 2017;
-Absolute Antibody “A brief history of antibodies”, 2017;
-David Davies “Antibodies Structure” Accounts of Chemical Research, volume 26, 1993;
-Burnet, F.M “A modification of Jerne’s theory of antibody production using the concept of clonal selection”, The Australian Journal of Science, volume 20, 1957;
-Köhler and Milstein “Continuous cultures of fused cells secreting antibody of predefined specificity”. Nature volume 256, 1975;
-Sgro C. “Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3” Toxicology Journal, volume 105, 1995;
-ChamesP ”Therapeutic antibodies: successes, limitations and hopes for the future”. Br J Pharmacol, volume 157, 2009;
-Reilly D.E ”Production of monoclonal antibodies in e. Coli. Curr Trends” Biotechnol Pharm Aspects, volume 10, 2010;
-Clementi N ”Phage display-based strategies for cloning and optimisation of monoclonal antibodies directed against human pathogens”, Int J Mol Sci, volume 13, 2012;
-Schirrmann T ”Phage display for the generation of antibodies for proteome research, diagnostics and therapy”, Molecules Journal, volum]e 16, 2011;
-Susha Cherivedath “Antibody Application”, News-Medical.net, Jan 2018.
-Nobel Prize Organization

Leave a Reply

Sorry, you must be logged in to post a comment.